The study suggests that TNFRSF9 may hold promise as a therapeutic target in PDA management, given its potential to inhibit tumor growth and modulate cell behavior.

P1, N=0, Withdrawn, Sichuan Baili Pharmaceutical Co., Ltd. | N=29 --> 0 | Recruiting --> Withdrawn

P1, N=29, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd.

P1, N=29, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd.

In summary, we combined a TCR of high natural anti-tumor reactivity for an HLA-A2-restricted PRAME- epitope with a chimeric PD1-41BB switch receptor that enhances T cell function and counteracts checkpoint- mediated dysfunction. This is a promising strategy to develop more effective TCR-T drug products for the treatment of solid cancers.

Moreover, DuoBody-PD-L1×4-1BB exhibits anti-tumor activity and induces memory immune responses in vivo. DuoBody-PD-L1×4-1BB is currently being evaluated in patients with advanced solid tumors in a first-in-human clinical trial (NCT03917381).

Expansions ranged from ~1,000 to 17,000 fold, which mainly depended on the starting cell number. In summary, these data provide proof of concept for the isolation and expansion of antigen-reactive T cells from tumor digest or peripheral blood in a closed, automated manner using the GMP-compliant CliniMACS Prodigy platform, allowing for the desired efficiency, simplicity and automated production of cellular products for ACT therapies against cancer.

These results suggest that iPS-ML-41BBL could activate antigen-specific T cells and promote their infiltration into the tumor tissues. Thus, iPS-ML-41BBL may be a candidate for future immune cell therapy aiming to change immunological "cold tumor" to "hot tumor".

P2, N=44, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2021 --> Mar 2022 | Trial primary completion date: Apr 2021 --> Sep 2021

The authors' novel bicistronic CD19/CD20 CAR T cells demonstrate improved anti-tumor efficacy in response to dual antigen stimulations. These data provide optimism that this novel bicistronic CAR construct can improve treatment outcomes in patients with relapsed/refractory B cell malignancy.

CD28 superiority was also demonstrated with HER2-specific CAR T cells (targeting ovarian carcinoma xenografts). Our findings encourage incorporating CD28 signaling into CAR design for adoptive T cell treatment of solid tumors.